AUS
NZ
UK
CA
USA
IND
Headlines:
- Q2 2024 Revenue and Earnings Expectations
- Stock Performance and Market Trends Analysis
- Valuation Insights and Future Outlook
Merck (NYSE:MRK) is scheduled to unveil its Q2 2024 financial results on Tuesday, July 30. Anticipations are set for the company to report revenue of approximately $15.9 billion and adjusted earnings of $2.20 per share, which is slightly above the consensus estimates. A major contributor to this anticipated growth is expected to be Keytruda, Merck's prominent cancer drug, with quarterly sales projected to exceed $7 billion, reflecting a significant year-over-year growth in the high teens percentage range. Additionally, the company's HPV vaccine, Gardasil, is forecasted to see its sales increase in the mid-teens percentage range. Although there are expectations for a strong performance in Q2, there is speculation that Merck's stock may have limited potential for further appreciation. Our interactive dashboard on Merck’s Earnings Preview offers a deeper dive into the company’s projected revenues and earnings for the quarter.
To understand what might influence Merck's results, it’s useful to review its recent stock performance. Over the past few years, MRK stock has risen by 55% from around $80 in early January 2021 to approximately $125 currently. This performance contrasts with the S&P 500, which has seen a 45% increase over the same period.On the other hand, the Trefis High Quality (HQ) Portfolio, consisting of 30 selected stocks, has outperformed the S&P 500 each year within the same timeframe, demonstrating better returns with reduced risk compared to the benchmark index.
Given the current macroeconomic uncertainties, including high oil prices and elevated interest rates, there is speculation about whether MRK might experience performance similar to 2021 and 2023 or if it will achieve substantial growth over the next year. In the context of healthcare stocks, Merck appears to be fairly valued with an estimated share price of $135, which is close to its current trading price of $127. Currently, MRK is trading at 5 times its revenues, compared to an average of 4.5 times over the past five years.
Examining the previous quarter, Merck reported revenue of $15.8 billion, marking a 9% increase year-over-year. This growth was driven by Keytruda, which saw a 20% year-over-year sales increase to $6.9 billion. Gardasil also saw a 14% rise in sales to $2.2 billion, while sales of Januvia/Janumet dropped by 24% due to rising competition. The company’s adjusted gross margin expanded by 430 basis points to 81.2%, attributable to a favorable product mix. This margin expansion contributed to a 48% increase in adjusted earnings per share to $2.07.
Looking ahead to the current quarter, Keytruda and Gardasil are expected to remain pivotal to Merck’s growth. Keytruda's expansion into new therapeutic areas is anticipated to bolster its market position, while Gardasil is projected to continue benefiting from strong demand, particularly in China. Nevertheless, Merck will face ongoing generic competition for its diabetes medications, Januvia/Janumet, in Europe. It will be important to monitor the operating margin trends for Merck in Q2, especially given the company’s management's expectations for margin expansion in 2024, following a robust expansion observed in Q1 of 2024.
While MRK stock is deemed reasonably priced, evaluating how Merck’s performance compares with its peers on key metrics provides valuable context. For further insights, comparisons with other companies across different industries can be explored in the Peer Comparisons section.
